Early Engagement with HTA Bodies
In-depth guide to successful early HTA engagement.
Jim Gallagher2021 年 5 月 10 日
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Watch this presentation to learn • Overview of the SNDS and the key working practices…
Jim Gallagher2021 年 5 月 7 日
Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States
Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou…
Jim Gallagher2021 年 4 月 8 日
Legislators: Bring all stakeholders to the table to lower drug costs
BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the…
Certara2021 年 3 月 30 日
Strategic Evidence & Value Communication Symposium
Join us on 2021 年 4 月 21 日, 星期三, from12:00 PM – 2:00 PM EDT for Certara’s…
Certara2021 年 3 月 26 日
Getting Gene Therapies to Patients
This blog discusses the challenges that drug developers face in getting patients access to cell…
Certara2021 年 2 月 16 日
Early Value Assessment in Gene Therapy Clinical Trial Design
A global biotechnology company engineering precision genetic medicine for rare diseases was in need of…
Jim Gallagher2021 年 2 月 12 日
Getting Real with RWE
By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…
Certara2020 年 11 月 20 日
SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU
In this webinar, our experts provided an overview of the SNDS and the key working…
Jim Gallagher2020 年 10 月 20 日
